2026

Corporate Presentation



Background image: Custom-designed Steriline vial production line at Canada's Critical Medicine's Production Centre

Disclaimer

This investor presentation (the "Investor Presentation") has been prepared by management of Vimy Pharmaceuticals Inc. ("Vimy Pharma" or the "Company") solely for information purposes. This Investor Presentation is not, and under no circumstances is to be construed to be, a prospectus, an offering memorandum or an offering of securities. Neither this Investor Presentation, nor its delivery to the recipient, shall constitute an offer to sell, or the solicitation of an offer to buy, any securities of the Company. The information contained in this document (a) is provided as at the date hereof and is subject to change without notice, (b) does not purport to contain all the information that may be necessary or desirable to fully and accurately evaluate an investment in the Company and (c) is not to be considered as a recommendation by the Company that any person make an investment in the Company. An investment in the securities of the Company is speculative and involves a number of risks that should be considered by an investor, including without limitation, those risks set forth in this Investor Presentation and in the Company's continuous disclosure documents filed under its profile on SEDAR+ at www.sedarplus.ca.

The information contained herein has been prepared to assist interested parties in making their own evaluation of the Company and its business and does not purport to contain all the information that investors may require. Investors should conduct their own investigation and analysis of the Company and its business and the information contained in this Investor Presentation, as well as the Company's continuous disclosure documents and any additional information provided by the Company.

This Investor Presentation also contains or references certain market, industry and peer group data which is based upon information from independent industry publications, market research, analyst reports and surveys and other publicly available sources. Although the Company believes these sources to be generally reliable, such information is subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other inherent limitations and uncertainties. The Company has not independently verified any of the data from third party sources referred to in this Investor Presentation and accordingly, the accuracy and completeness of such data is not guaranteed.

This Investor Presentation contains references to trademarks and service marks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Investor Presentation may appear without the ® or ™ symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. The Company does not intend the use or display of other companies' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of the Company by, any other companies.

Investors should be aware that the purchase of securities of the Company may have tax consequences. The Company assumes no responsibility for the tax consequences of any investment. Each investor is strongly encouraged to consult its own tax advisor concerning any purchase of securities of the Company.

The securities of the Company have not been, and will not be, registered under the U.S. Securities Act of 1933 (the "Securities Act"), or the securities laws of any state of the U.S., and may not be offered or sold within the U.S., except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state or local securities laws.

© VIMY PHARMACEUTICALS INC. All rights reserved.

Cautionary Note Regarding Forward-Looking Statements

Statements in this Investor Presentation, including the information set forth as to the future financial or operating performance of the Company, that are not current or historical factual statements may constitute "forward-looking" information within the meaning of applicable securities laws. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. When used in this Investor Presentation, such statements may include, among other language, such words as "may", "will", "expect", "believe", "plan", "anticipate", "intend", "estimate" and other similar terminology. These statements reflect current expectations, estimates and projections regarding future events and operating performance and speak only as to the date of this Investor Presentation. Readers should not place undue reliance on forward-looking statements and should not rely upon this information as of any other date. These forward-looking statements involve a number of risks and uncertainties including, but not limited to:

- failure to obtain approval from Health Canada for the Company's semaglutide products and production sites, on the anticipated timeline or at all;
- failure to obtain timely receipt of any other required regulatory approvals;
- ongoing oversight and review of the Company's products and facilities by regulatory and governmental agencies, including Health Canada and, if applicable, equivalent agencies outside of Canada, which can potentially delay facility inspections and product approvals critical to the Company's supply continuity and new product launches and/or result in import and export restrictions and the halting of production at the facilities of manufacturing partners;
- ability of the Company's manufacturing partners to perform to the required specifications of the Company's products resulting in delays or issues with the Company's submissions or products;
- ability to obtain components, raw materials or products supplied by third parties and other manufacturing and related supply difficulties, interruptions and delays;
- failure to raise sufficient funding to meet development plans and budgets, satisfy contractual obligations and additional capital needs generally;
- ability to maintain and enforce the protection afforded by any intellectual property or regulatory exclusivity rights;
- the impact of changing conditions and increasing competition in the pharmaceutical and branded consumer health and wellness markets;
- ability to compete against companies that are larger and have greater financial, technical and human resources than the Company, as well as other competitive factors, such as technological advances achieved, patents obtained and new products introduced by competitors;
- reliance on third party contract manufacturers to manufacture the Company's products on favourable terms;
- risk of patent applications and/or granting of patents of similar products being filed by a competitor;
- the Company's lack of operating history;
- ability to bring products to market first, or to do so in a timely and cost-efficient manner or in a manner sufficient to grow the Company's business, replace lost revenue resulting from industry-wide price erosion or take advantage of new technological efficiencies, including artificial intelligence and quantum computing;
- changes in prescription recommendations or behaviours by clinical commissioning groups or other healthcare groups in Canada or any future jurisdictions in which the Company may sell its products;
- risks of litigation, including product liability claims or recalls, sales and marketing practices, intellectual property disputes, anti-trust claims and government investigations generally;
- changes or disruptions in financial markets;
- increased infrastructure, marketing and/or operating costs;
- limits of insurance coverage and uninsurable risk;
- failure to comply with laws and regulations or other regulatory requirements;
- the inability of the Company to retain its key management employees and shortages of skilled personnel and contractors;
- influence of third party stakeholders;
- failures or deficiencies in the Company's system of internal controls;
- conflicts of interest;
- credit and/or liquidity risks;
- general regulatory environment in which the Company operates, including the areas of taxation, environmental protection, consumer safety and health regulation;
- political instability, hostilities, insurrection or acts of war or terrorism;
- adverse changes in government legislation and regulation;
- general business, economic, competitive, political, regulatory and social uncertainties; and
- the risks involved in the generic pharmaceutical business generally.

The forward-looking statements included in this Investor Presentation are made only as of the date of this Investor Presentation and the Company undertakes no obligation to update any forward looking-statements to reflect subsequent events or circumstances. There can be no assurance that the projected results can be realized or that actual results will not be materially higher or lower than those projected.

© VIMY PHARMACEUTICALS INC. All rights reserved.

Generic GLP-1 medicines, manufactured in Canada. **Reliable. Affordable. Canadian.**

© VIMY PHARMACEUTICALS INC. All rights reserved.


Semaglutide is the most widely used peptide in Canada, and Canada is the second largest semaglutide market in the world, with a current market size of approximately **$4.1B.**[1]

Canada is the **first G7 jurisdiction** to allow **generic semaglutide sales** while the US and EU are expected to remain patent-protected until 2031 and beyond.[2] Domestic manufacturers have an opportunity, which may be amplified by Health Canada's potential pilot to **prioritize certain generic drug submissions involving domestic manufacturing within the regulatory review queue.**[3]

By 2030, it is projected that the Canadian market may grow to **$8B a fraction of the total addressable market ("TAM") of 20M patients.**[4] Vimy Pharma is poised to be on the front line. We are a **Canadian manufacturer** of generic glucagon-like peptide-1 (**"GLP-1"**) (Ozempic® and Wegovy®) submitted to Health Canada.

With former Novo Nordisk talent at the helm, Vimy Pharma manufactures products in a unique vial form. Initial progress with key development milestones achieved has materially de-risked the business, and other major **milestones are already in sight.**

We expect to begin **selling both Vimy-Semaglutide (diabetes) and Vimy-Semaglutide (weight management ("WT")) in H2-2027.**



Please see Disclaimer and Cautionary Note Regarding Forward-Looking Statements on slides 2 and 3.

[1] Health Canada, "Peptides: Overview," Government of Canada, updated October 23, 2026; Apotex Health Corp., FQ2/27 Preview: Last tough comp before H2, inflection; gOzempic opportunity revised higher, Doug Miehm, 6 October 2026 (attributed to SDM/Loblaws); .

[2] Reddie & Grose LLP, *Changes in the Ozempic Patent Landscape*, 9 February 2026. Available at: www.reddie.co.uk/2026/02/09/changes-in-the-ozempic-patent-landscape/ (accessed August 2026)

[3] Health Canada, "Consultation on a proposed pilot approach to prioritize certain generic drug submissions involving domestic manufacturing within the review queue," Government of Canada, updated October 5, 2026..

[4] Apotex Health Corp., FQ2/27 Preview: Last tough comp before H2, inflection; gOzempic opportunity revised higher, Doug Miehm, 6 October 2026 (attributed to SDM/Loblaws); UBS Global Research, Eli Lilly and Co., Michael Yee et al., 16 July 2026 Statistics Canada CHMS (2022-2024); 68% of Canadian adults are overweight or living with obesity.

© VIMY PHARMACEUTICALS INC. All rights reserved.

01

Vimy Pharma

Uniquely qualified team and development milestones.



Vimy Pharma Leadership

Brings significant experience to semaglutide in Canada



Dave Suchon

CEO & Co-Founder & Director

- 20+ years in Canadian pharma
- 12 years at Novo Nordisk; Executive leadership; Regulatory, Quality, Legal, Communications, Lobbying
- Led Health Canada approval of Ozempic®
- Biochemistry study and research in protein chemistry
- Pharma regulatory lawyer & patent litigator



Farris Smith

President & Co-Founder & Director

- 25+ years in global pharma, 20 at Novo Nordisk
- Novo Nordisk regional CFO and management roles across Europe, LATAM, Middle East & Africa, and Canada
- North American CFO, LEO Pharma
- Strategic Advisor, Arch Biopartners (TSXV: ARCH)



Jo-anne Soltesz

Head of Regulatory

- 30+ years global pharma regulatory leadership
- Injectable & generic expertise
- Experience at Sandoz, Agri Mix & SteriMax
- Led 50+ Canadian generic drug submissions
- Senior regulatory leader in Canada & Europe



Chris Burkett

COO, GC, Co-Founder & Director

- Former National Leader, Legal Market at Deloitte
- Former partner at an internationally renowned law firm
- Advised complex, regulated industries, including pharma, on litigation, compliance & growth strategy
- Founding executive, award-winning sports league

© VIMY PHARMACEUTICALS INC. All rights reserved.

Board of Directors

Trusted governance

Dave Suchon

CEO, Co-Founder & Director

Farris Smith

President, Co-Founder & Director

Chris Burkett

COO, GC, Co-Founder & Director

Riccardo Trecroce

Director

- Chair of Halton Healthcare
- Former CEO of Patheon, a multinational pharma manufacturing leader (now part of Thermo Fisher)
- Senior legal and governance executive

Darryl Firsten

Director

- Founder of Convocation Flowers, one of North America's leading graduation retail platforms
- Chemical engineer with 20+ years building multi-jurisdictional businesses

Zachary Goldenberg

Director

- Significant Canadian public board experience, including audit committees
- Corporate and securities lawyer
- Former Chair of the Audit Committee, Tiidal Gaming Group
- Former member, TSX Venture Exchange Ontario Advisory Committee

Uniquely well-suited team for the opportunity

© VIMY PHARMACEUTICALS INC. All rights reserved.

Multiple Milestones
Recent Progress

Significant milestones achieved by Vimy Pharma in 2026

Generic Ozempic® filed
~5,000-page submission filed in May 2026 with Health Canada for Vimy-semaglutide (reference product: Ozempic®)

Generic Wegovy® filed
~7,500-page submission filed in August 2026 with Health Canada for Vimy-semaglutide (WT) (reference product: Wegovy®)

Health Canada Screening Acceptance
Vimy-semaglutide & Vimy-semaglutide (WT) successfully screened and accepted by Health Canada into review


Priority Review Policy
Health Canada proposed pilot approach to prioritize certain generic drug submissions involving domestic manufacturing within the regulatory review queue[5]

Poised to enter Canadian market and expand internationally

African Business Coalition for Health
- Partnership seeking to bring Vimy-semaglutide and Vimy-semaglutide (WT) to multiple African countries


Other International Partnership
- Commercial agreement to supply Vimy Pharma products to 10+ countries in middle east and beyond

Potential offset to Canadian Pharma trade deficit
- Pharma trade deficit is widening
- $5.5B (2016) → $14.6B (2025)[6]
- Limited domestic production



Please see Disclaimer and Cautionary Note Regarding Forward-Looking Statements on slides 2 and 3.
[5] Health Canada. "Notice: Health Canada seeks feedback on a proposed pilot approach to prioritize certain generic drug submissions involving domestic manufacturing within the regulatory review queue." July 15, 2026. Available at: https://www.canada.ca/. Accessed August 12, 2026.
[6] Statistics Canada Trade Data Online; ISED Canadian Industry Statistics (NAICS 32541), 2016-2025.

© VIMY PHARMACEUTICALS INC. All rights reserved.



Vimy Pharma Is Driving Canadian GLP-1 Production

Uniquely Qualified

Novo Nordisk veteran leadership (30+ years); led Ozempic® Health Canada approval

Top Canadian experts across clinical semaglutide, GLP-1 chemistry, and generics with Health Canada

Advanced Process

Health Canada-informed testing program

Traditional assays + advanced orthogonal, peptide-specific methods

Robust Results

Q2 2026: Development work complete; **with data readout**

Milestone: two generic submissions to Health Canada

$22.5M

Fully funded through development and approval

© VIMY PHARMACEUTICALS INC. All rights reserved.

Introducing Vimy-Semaglutide

Canadian manufactured generic GLP-1 injectable formulation

Vimy Pharma has developed generic semaglutide referencing Ozempic® and Wegovy®

Manufactured in **vials:**

- The most widely used format for injectable medicines, used by millions in North America for GLP-1-based medicines
- A smaller package offsets limited refrigerator capacity at wholesalers and in pharmacies
- Ubiquitous vial and component supply avoids potential bottlenecks in generic pen supply[7]



Demonstration only. Submission, including packaging and labelling is currently under review and subject to the final determination by Health Canada.

[7] Management commentary. Jeff Watson (CEO of Apotex) comments on GLP-1 pen supply constraints and manufacturing bottlenecks; Apotex Q1 FY2027 Earnings Call Transcript, Investing.com, Aug. 12, 2026; UBS Global Research, *Eli Lilly and Co.*, Michael Yee et al., 16 July 2026.

© VIMY PHARMACEUTICALS INC. All rights reserved.

02

The GLP-1 Landscape in Canada

An expanding market.



Canadian GLP-1 market is unique and growing

Canada is the 2nd largest semaglutide market[8]

$4.1B market[9]

31% yoy growth in 2025[9]

Injectable format preferred

As compared to the pill format[12]

Currently at 6% TAM

- 1M Canadian users[10]
- ~20M Canadians living with overweight or obesity[11]



Canada is **currently dependent on foreign manufacturing** for supply of semaglutide drug products

- Manufacturing of branded semaglutide occurs outside of Canada
- Generic semaglutide from Apotex and Dr. Reddy's appears to be made in India

> *"Canada's access to new medicines is increasingly at risk. Recent global developments, including the introduction of the most favoured nation drug pricing in the United States, is already disrupting access to existing medicines, delaying or halting the launch of new medicines and undermining confidence in Canada's pharmaceutical market."*[13]

U.S. scale creates risks to pharmaceutical sovereignty

- U.S. sales represent 68% of total sales for branded semaglutide[14]

[8] Sandoz management commentary. Richard Saynor identified Canada as the world's second-largest GLP-1 market (GLP1Prices.ca, Apr. 2026)

[9] Apotex Health Corp., FQ2/27 Preview: Last tough comp before H2, inflection; gOzempic opportunity revised higher, Doug Miehm, 6 October 2026 (attributed to SDM/Loblaws); Chris Hannay, "Canada will be a launching pad in the global race for generic Ozempic," The Globe and Mail (30 January 2026; updated 31 January 2026).

[10] IQVIA, MAT May 2026, assuming 1 patient uses 13 package units per year.

[11] Statistics Canada CHMS (2022-2024); 68% of Canadian adults are overweight or living with obesity; UBS Global Research, *Eli Lilly and Co.*, Michael Yee et al., 16 July 2026.

[12] Rybelsus® (pill format of Ozempic® launched in April 2020) had 2025 sales of ~$100M compared to Ozempic® with sales of $2.9B.

[13] Bettina Hamelin (President and Chief Executive Officer, IMC), March 10, 2026. https://www.ourcommons.ca/DocumentViewer/en/45-1/HESA/meeting-24/evidence#Int-13395727

[14] Novo Nordisk, Annual Report 2025.

© VIMY PHARMACEUTICALS INC. All rights reserved.

03

The Opportunity

A clear window to act.



Market may grow to $8B by 2030, a fraction of the TAM of 20M patients[15]

[15] Apotex Health Corp., FQ2/27 Preview: Last tough comp before H2, inflection; gOzempic opportunity revised higher, Doug Miehm, 6 October 2026 (attributed to SDM/Loblaws); UBS Global Research, Eli Lilly and Co., Michael Yee et al., 16 July 2026 Statistics Canada CHMS (2022-2024); 68% of Canadian adults are overweight or living with obesity.

Please see Disclaimer and Cautionary Note Regarding Forward-Looking Statements on slides 2 and 3.

Background image: Custom-designed Steriline vial production line for Vimy-semaglutide at Canada's Critical Medicine's Production Centre

© VIMY PHARMACEUTICALS INC. All rights reserved.

04

Further Perspective



More Value at Home

Through Canadian production

Taxes in Canada

Vimy Pharma's full profit margin will be taxed by the CRA.[16]

Skilled Jobs

Vimy Pharma supports **high-value life sciences employment** in Ontario and Alberta and beyond, while contributing to advanced manufacturing capacity.

Economic Value

Over time, we believe increased domestic production can substantially narrow Canada's growing pharmaceutical trade deficit and retain more intellectual property and economic value within Canada.

Value that stays in Canada.

Please see Disclaimer and Cautionary Note Regarding Forward-Looking Statements on slides 2 and 3.

[16] IMC members reported an operating profit margin of 1.8%, 0.7% and 3% in Canada for the years of 2021, 2022 and 2023 (section 3.1.2: https://www150.statcan.gc.ca/n1/pub/11-621-m/11-621-m2025004-eng.htm; https://www150.statcan.gc.ca/n1/pub/11-621-m/11-621-m2026001-eng.htm)

© VIMY PHARMACEUTICALS INC. All rights reserved.

Aligned to Federal Policy

This initiative directly supports current federal economic and industrial objectives.

A **Canadian-owned** and **manufactured** Vimy-semaglutide and Vimy-semaglutide (WT) supply aligns with the government's focus on domestic production, resilient supply chains, and Buy Canadian procurement approaches.

It reinforces federal investments in the life sciences sector while ensuring that intellectual property, talent, and economic returns remain anchored in Canada.

→ **To be manufactured in Edmonton, at Applied Pharmaceutical Innovation's Critical Medicines Production Center, established with over $130M in federal funding[17]**



"Canadians have made a choice: to focus on what we can control… we will build big with Canadian technology and with Canadian workers. We can't control what other nations do. We can be our own best customer. We'll buy Canadian. We'll build Canadian. And together, we will build Canada strong."

— Prime Minister Mark Carney, January 24, 2026

Please see Disclaimer and Cautionary Note Regarding Forward-Looking Statements on slides 2 and 3.

[17] Government of Canada, additional investment in the Canadian Critical Drug Initiative, Apr. 2026 (https://www.canada.ca/en/prairies-economic-development/news/2026/04/government-of-canada-announces-additional-investment-to-support-the-canadian-critical-drug-initiative.html)

© VIMY PHARMACEUTICALS INC. All rights reserved.

Capitalization & Ownership


- Vimy Pharmaceuticals Corp. completed a $14.5 million brokered private placement of subscription receipts at $3.00 per subscription receipt and completed its go-public transaction through a reverse takeover of Harmony Acquisitions Corp., a capital pool company in November 2026

Capitalization

RTO Financing Price ($)	$3.00
Shares Outstanding	32.3M

Principal shares are escrowed under TSXV Tier 2 policy: 10% released at listing, then 15% every six months. Directors, officers and significant shareholders are also subject to 12-month lock-ups.

Ownership



Please see Disclaimer and Cautionary Note Regarding Forward-Looking Statements on slides 2 and 3.

© VIMY PHARMACEUTICALS INC. All rights reserved.

Contact

Chris Burkett, COO, GC & Co-Founder

Dave Suchon, CEO & Co-Founder

Farris Smith, President & Co-Founder

www.vimypharma.com

ir@vimypharma.com

Vimy Pharmaceuticals Corp.

2 Bloor Street West, Suite 2002, Toronto, ON M4W 3E2

